Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 October 2024 | Story Anthony Mthembu | Photo Stephen Collett
Sanlam and Santam Economist of the Year’ competition
From left to right: Jaco Geldenhuys, Senior Business Manager at Sanlam; Mokai Malope, secured second place; Reatile Seekoei, winner of the 2024 Sanlam and Santam Economist of the Year competition; Tricia Khoza, secured third place; and LC Olivier, Senior Business Manager at Santam.

The inaugural ‘Sanlam and Santam Economist of the Year’ competition gala, held on 18 October 2024 at the University of the Free State (UFS) Bloemfontein Campus, has been hailed as a significant opportunity for growth. Hosted by the Department of Economics and Finance in the Faculty of Economic and Management Sciences (EMS), in collaboration with Sanlam and Santam, the event celebrated the exceptional talents of young economists.

The gala brought together representatives from Sanlam and Santam, faculty members, the top 10 competition finalists, and the department’s leading academic performers from each year group. Jaco Geldenhuys, Senior Business Manager at Sanlam, commended the participants for their dedication, noting: ’Today, we not only recognise your academic excellence but also the potential, positive impact you will have in the world.’’

Prof Johan Coetzee, Chairperson of the Department of Economics and Finance, echoed this sentiment, emphasising that the competition aims to equip graduates to become global citizens who can solve problems, think critically, and communicate effectively in a constantly changing world.

What transpired during the event

The top 10 finalists presented their analysis in a 6-minute presentation before a panel of economists from the department, demonstrating their understanding of the macroeconomic environment, the methods they used to predict key macroeconomic indicators, and the lessons they gained from the process. After these presentations, the top three finalists were chosen and were required to respond to questions from the panel, determining the overall winner.

The top three included Tricia Khoza, who secured third place, Mokai Malope, who earned second place; and Reatile Seekoei, who was named the 2024 ‘Sanlam and Santam Economist of the Year.

All three finalists expressed their gratitude for the opportunity. Seekoei shared: “Competitions like this are invaluable because they prepare us for the working world. We have gained several graduate attributes we were introduced to at the start of our academic journey.’’

In addition to recognising the top three finalists, the department also awarded certificates to its top academic achievers, ranging from first-year undergraduate students to master's candidates.

Paving the way for the future

For many of the participants, the competition provided an invaluable glimpse into the professional world, offering them a chance to apply their classroom learning to real-world economic challenges. Geldenhuys encouraged the young economists to use their knowledge to challenge inequality, promote fairness, and drive innovation and sustainable growth.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept